The science of lifespan extension, stripped of the sales pitch.
We analyze clinical trials, biomarker protocols, and supplement efficacy. No sponsored content. No manufacturer kickbacks. Just rigorous data to guide your healthspan investments.
Latest Research Briefs
-
NAD+ Precursors: NMN vs NR
A meta-analysis of human trials regarding pharmacokinetics. Read more →
-
ApoB: The New Lipid Standard
Why LDL-C is insufficient and ApoB targets for cardiovascular longevity. Read more →
-
Off-Label Rapamycin Dosing
Reviewing weekly pulsatile dosing regimens used in longevity clinics. Read more →
-
Fisetin: Mayo Clinic Protocol
High-dose pulsatile protocol for senescent cell clearance. Read more →
Our Editorial Stance
The longevity industry is plagued by conflicts of interest. The majority of content is produced by companies selling the very supplements they are "reviewing".
We take a different approach. We strictly rely on human clinical trial data, documented physiological pathways, and transparent biomarker targets to evaluate interventions.